By Suherman Candra Maholtra 
A groundbreaking large-scale study presented at the American College of Cardiology’s Annual Scientific Session (ACC.26) has revealed that the shingles vaccine provides a profound protective effect for individuals already diagnosed with heart disease. Researchers found that patients with atherosclerotic cardiovascular disease who received the vaccine experienced nearly half the rate of serious heart-related events within one year compared to their unvaccinated counterparts. These findings suggest that the clinical utility of the shingles vaccine—traditionally administered to prevent a painful skin condition—may extend into the realm of preventative cardiology, offering a dual-purpose intervention for the aging population.
The study, led by Dr. Robert Nguyen, a resident physician at the University of California, Riverside, scrutinized the medical histories of more than 246,000 adults in the United States. The focus was specifically on those with atherosclerotic heart disease, a condition characterized by the accumulation of fats, cholesterol, and other substances in and on the artery walls. This plaque buildup can restrict blood flow and, if a plaque ruptures, can trigger a blood clot that leads to a heart attack or stroke. By targeting this high-risk demographic, the research highlights a significant opportunity to mitigate life-threatening complications through standard immunization protocols.
Methodology and the Use of Real-World Data
To arrive at these conclusions, the research team utilized TriNetX, a sophisticated and expansive global health research network that provides access to de-identified electronic health records from millions of patients across various healthcare organizations in the United States. This "big data" approach allowed the researchers to identify a massive cohort of adults aged 50 and older who were diagnosed with atherosclerotic disease between the years 2018 and 2025.
The analysis was meticulously structured to ensure a balanced comparison. Researchers identified 123,411 individuals who had received at least one dose of a shingles vaccine—either the older Zostavax (a live attenuated vaccine) or the more modern and widely used Shingrix (a recombinant, adjuvanted vaccine). This group was then matched with an equal number of unvaccinated individuals (123,411) who shared similar demographic profiles, including age, gender, and race.
Crucially, the researchers employed propensity score matching to account for various confounding health conditions and socioeconomic variables. These included factors such as housing stability, economic circumstances, education levels, and employment status. By controlling for these variables, the team aimed to isolate the effect of the vaccine itself, minimizing the "healthy user bias"—the tendency for people who seek out vaccines to also engage in other heart-healthy behaviors.
Quantitative Findings: A Dramatic Reduction in Risk
The data revealed a striking disparity in health outcomes between the two groups during the follow-up period, which spanned from one month to one year following vaccination. The primary metric used was Major Adverse Cardiac Events (MACE), a composite endpoint frequently used in clinical trials to measure the overall cardiovascular safety and efficacy of an intervention.
According to the study’s results, vaccinated individuals were 46% less likely to experience a major adverse cardiac event than those who were not vaccinated. When the data was broken down into specific cardiovascular complications, the protective benefits remained consistent across the board:
- All-Cause Mortality: The risk of death from any cause was 66% lower in the vaccinated group.
- Myocardial Infarction (Heart Attack): The risk of suffering a heart attack dropped by 32%.
- Stroke: The incidence of stroke was 25% lower among those who received the vaccine.
- Heart Failure: Vaccinated patients saw a 25% reduction in the risk of developing or exacerbating heart failure.
Dr. Nguyen emphasized the magnitude of these statistics, noting that a 46% reduction in major events is a clinical milestone rarely achieved by a single lifestyle change or medication. He compared the scale of these benefits to the positive health impacts seen when a long-term smoker finally quits the habit.
The Biological Link Between Shingles and the Heart
The biological rationale behind these findings lies in the relationship between viral infection and systemic inflammation. Shingles is caused by the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox. After a person recovers from chickenpox, the virus remains dormant in the nerve tissues near the spinal cord and brain. As the immune system weakens with age or stress, the virus can re-emerge as shingles, characterized by a painful, blistering rash.
However, the impact of VZV is not limited to the skin and nerves. Previous clinical research has demonstrated that a shingles outbreak can trigger a cascade of inflammatory responses throughout the body. During an active infection, the virus can cause vasculopathy—an inflammation of the blood vessels—which increases the likelihood of blood clots. These clots can block blood flow to the heart or brain, directly causing heart attacks or strokes.
Furthermore, chronic inflammation is a known driver of atherosclerosis. By preventing the reactivation of VZV, the shingles vaccine effectively removes a significant inflammatory trigger. This "cardioprotective" effect suggests that the vaccine acts as a stabilizing force, preventing the sudden inflammatory spikes that often lead to the rupture of arterial plaques in patients with existing heart disease.
Contextualizing the Shingles Vaccine in Public Health
The Centers for Disease Control and Prevention (CDC) currently recommends that adults aged 50 and older receive two doses of the Shingrix vaccine, spaced two to six months apart. The recommendation also extends to adults 19 and older who have weakened immune systems due to disease or therapy. While the primary goal of these recommendations has been the prevention of shingles and its most common complication, postherpetic neuralgia (persistent nerve pain), the new data from ACC.26 adds a compelling cardiovascular argument to the existing guidelines.
The evolution of shingles vaccines has also played a role in these findings. Zostavax, which was used for many years, was found to be significantly less effective than the newer Shingrix. Shingrix, introduced in 2017, has shown an efficacy of over 90% in preventing shingles in clinical trials. The shift toward this more potent recombinant vaccine may contribute to the strong cardiovascular protection observed in the most recent data cohorts from 2018–2025.
Expert Perspectives and Addressing Vaccine Hesitancy
The presentation of this study comes at a time when public health officials are grappling with varying levels of vaccine hesitancy. Dr. Nguyen noted that in an era often characterized by medical disinformation, providing patients with "off-target" benefits—such as heart protection—can be a powerful tool for clinicians.
"Vaccines are one of the most important medicines we have to prevent disease," Dr. Nguyen stated. He explained that for a patient with heart disease, the decision to get a shingles vaccine might be swayed by the knowledge that it could prevent a future heart attack, rather than just a skin rash.
Cardiologists attending the ACC session have noted that these findings could lead to a more integrated approach to patient care. It is becoming increasingly common for specialists to view immunizations as part of a comprehensive cardiovascular prevention strategy, alongside statins, blood pressure medication, and antiplatelet therapy. The integration of "immunometabolism"—the study of how the immune system and metabolism interact—is a burgeoning field that this study directly supports.
Long-term Implications and Future Research
While the one-year data is remarkably positive, researchers acknowledge that further study is needed to determine the longevity of this protection. A separate study published in 2025 indicated that the cardiovascular benefits of the shingles vaccine could last up to eight years in generally healthy adults, though the reduction in risk was lower (approximately 23%) compared to the 46% seen in the high-risk heart disease group studied by Dr. Nguyen.
This discrepancy suggests that those with the most to lose—patients with advanced atherosclerosis—may actually have the most to gain from the vaccine. The heightened state of inflammation in heart disease patients may make them more susceptible to the "pro-thrombotic" (clot-promoting) effects of a shingles flare-up, thereby making the vaccine’s preventive role even more critical.
One limitation cited by the research team is the observational nature of the study. Despite rigorous matching, it remains difficult to fully account for every behavioral difference between vaccinated and unvaccinated individuals. However, the sheer size of the study—nearly a quarter of a million people—provides a high level of statistical power that reinforces the validity of the association.
Conclusion: A New Frontier in Preventative Cardiology
The study "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease" is set to be a focal point of discussion at the ACC.26 conference. As Dr. Nguyen prepares to present the findings on March 30, the medical community is already considering how this data might influence clinical practice.
For the millions of Americans living with heart disease, the shingles vaccine may represent a low-risk, high-reward intervention. If the findings continue to be supported by longitudinal data, the shingles vaccine could be reclassified in the minds of both doctors and patients—not just as a defense against a painful rash, but as a vital shield for the heart.
The broader implications are clear: by addressing the viral and inflammatory triggers of cardiovascular events, healthcare providers can potentially save thousands of lives and reduce the massive economic burden associated with heart failure hospitalizations and stroke rehabilitation. As the population ages and the prevalence of both shingles and heart disease remains high, the intersection of immunology and cardiology represents a promising new frontier in public health.
